CEP-33779

• Description:

  CEP-33779 is a novel, selective, and orally bioavailable inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  JAK

• Type:

  Reference compound

• Related Pathways:

  Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/CEP-33779.html

• Purity:

  99.23

• Solubility:

  DMSO : 8.33 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=S(C1=CC=C(C2=CC=CN3C2=NC(NC4=CC=CC(N5CCN(C)CC5)=C4)=N3)C=C1)(C)=O

• Molecular Formula:

  C24H26N6O2S

• Molecular Weight:

  462.57

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Dugan BJ, et al. A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779. J Med Chem. 2012 Jun 14;55 (11) :5243-54.|[2]Seavey MM, et al. Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer. Mol Cancer Ther. 2012 Apr;11 (4) :984-93.|[3]Tang SJ, et al. CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function. Biochem Pharmacol. 2014 Sep 15;91 (2) :144-56.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  JAK2; JAK3

• CAS Number:

  [1257704-57-6]